Site icon Volume 12 Number 7

Clinical Trials

By Marta Catalfamo

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
ClinicalTrials.gov Identifier: NCT05080790
Recruitment Status : Recruiting
First Posted : October 18, 2021
Last Update Posted : June 3, 2022
See Contacts and Locations

Serum Interleukin – 17A in Juvenile Idiopathic Arthritis
ClinicalTrials.gov Identifier: NCT05688358
Recruitment Status : Not yet recruiting
First Posted : January 18, 2023
Last Update Posted : January 18, 2023
See Contacts and Locations

Beta Endorphins,Interleukin 1 and Interleukin 38 in Covid Patients Associated With Neuropsychological Manifestations.
ClinicalTrials.gov Identifier: NCT05198388
Recruitment Status : Recruiting
First Posted : January 20, 2022
Last Update Posted : January 25, 2022
See Contacts and Locations

THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS
ClinicalTrials.gov Identifier: NCT05585957
Recruitment Status : Not yet recruiting
First Posted : October 19, 2022
Last Update Posted : October 19, 2022
See Contacts and Locations

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
ClinicalTrials.gov Identifier: NCT04911166
Recruitment Status : Recruiting
First Posted : June 2, 2021
Last Update Posted : April 24, 2023
See Contacts and Locations

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
ClinicalTrials.gov Identifier: NCT03030378
Recruitment Status : Recruiting
First Posted : January 25, 2017
Last Update Posted : September 28, 2023
See Contacts and Locations

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)
ClinicalTrials.gov Identifier: NCT04154826
Recruitment Status : Recruiting
First Posted : November 7, 2019
Last Update Posted : March 31, 2022
See Contacts and Locations

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
ClinicalTrials.gov Identifier: NCT03882307
Recruitment Status : Recruiting
First Posted : March 20, 2019
Last Update Posted : July 26, 2022
See Contacts and Locations

Performance of Interleukin-27 Cord Blood Level as A Biomarker Predicating Early Onset Neonatal Sepsis
ClinicalTrials.gov Identifier: NCT05589909
Recruitment Status : Recruiting
First Posted : October 21, 2022
Last Update Posted : October 21, 2022
See Contacts and Locations

Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study
ClinicalTrials.gov Identifier: NCT05855460
Recruitment Status : Recruiting
First Posted : May 11, 2023
Last Update Posted : May 11, 2023
See Contacts and Locations

Low Dose IL-2 for the Treatment of Crohn’s Disease
ClinicalTrials.gov Identifier: NCT04263831
Recruitment Status : Recruiting
First Posted : February 11, 2020
Last Update Posted : July 18, 2023
See Contacts and Locations

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART)
ClinicalTrials.gov Identifier: NCT04017936
Recruitment Status : Recruiting
First Posted : July 12, 2019
Last Update Posted : November 7, 2023
See Contacts and Locations

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)
ClinicalTrials.gov Identifier: NCT04426201
Recruitment Status : Active, not recruiting
First Posted : June 11, 2020
Last Update Posted : April 8, 2022

Interleukin-34 Level in Periodontal Disease
ClinicalTrials.gov Identifier: NCT05962567
Recruitment Status : Recruiting
First Posted : July 27, 2023
Last Update Posted : July 27, 2023
See Contacts and Locations

Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepss
ClinicalTrials.gov Identifier: NCT05640037
Recruitment Status : Recruiting
First Posted : December 7, 2022
Last Update Posted : June 28, 2023
See Contacts and Locations

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
ClinicalTrials.gov Identifier: NCT05094570
Recruitment Status : Recruiting
First Posted : October 26, 2021
Last Update Posted : November 30, 2023
See Contacts and Locations

Interferon Alpha Therapy for Cervical CINI and HPV Infection
ClinicalTrials.gov Identifier: NCT06137950
Recruitment Status : Recruiting
First Posted : November 18, 2023
Last Update Posted : November 18, 2023
See Contacts and Locations

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)
ClinicalTrials.gov Identifier: NCT05843786
Recruitment Status : Recruiting
First Posted : May 6, 2023
Last Update Posted : September 14, 2023
See Contacts and Locations

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia
ClinicalTrials.gov Identifier: NCT04226950
Recruitment Status : Recruiting
First Posted : January 13, 2020
Last Update Posted : November 15, 2023
See Contacts and Locations

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
ClinicalTrials.gov Identifier: NCT04979052
Recruitment Status : Recruiting
First Posted : July 27, 2021
Last Update Posted : November 3, 2023
See Contacts and Locations
To Evaluate the Clinical Efficacy and Safety of Recombinant Human Interferon ω Spray in Treatment of Viral Upper Respiratory Tract Infection in Children
ClinicalTrials.gov Identifier: NCT05859984
Recruitment Status : Not yet recruiting
First Posted : May 16, 2023
Last Update Posted : May 16, 2023
See Contacts and Locations

Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections (INTERFERICUS)
ClinicalTrials.gov Identifier: NCT05536219
Recruitment Status : Recruiting
First Posted : September 10, 2022
Last Update Posted : November 18, 2023
See Contacts and Locations

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)
ClinicalTrials.gov Identifier: NCT06053749
Recruitment Status : Not yet recruiting
First Posted : September 26, 2023
Last Update Posted : November 18, 2023
See Contacts and Locations

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
ClinicalTrials.gov Identifier: NCT03120624
Recruitment Status : Recruiting
First Posted : April 19, 2017
Last Update Posted : November 15, 2023
See Contacts and Locations

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
ClinicalTrials.gov Identifier: NCT05953545
Recruitment Status : Not yet recruiting
First Posted : July 20, 2023
Last Update Posted : November 30, 2023
See Contacts and Locations

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)
Principal Investigators: Inge Marie Svane, MD. CCIT, Herlev Hospital, Copenhagen University. Copenhagen, Denmark
Contact:. Inge Marie Svane, MD. Phone: +45 38 68 38 68
ClinicalTrials.gov Identifier: NCT04217473

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
Principal Investigators: Peter Reichardt, MD. Helios Klinikum Berlin-Buch. Berlin, Germany, 13125
Contact: Daniel Pink, MD. Phone: 033631 73527
ClinicalTrials.gov Identifier: NCT05080790

Targeting IL-17A for Treatment-Resistant Depression
Principal Investigators: James W Murrough, MD, PhD. Icahn School of Medicine at Mount Sinai. New York, New York, United States, 10025
Contact: Mirabel Sleiman, BA. Phone: +1 212-585-6136
ClinicalTrials.gov Identifier: NCT04979910

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (TRANSFORM)
Principal Investigators: Atsushi Kawakami, MD, PhD. Nagasaki University Hospital. Nagasaki, Japan, 852-8501.
Contact: Atsushi Kawakami, MD, PhD. Phone: +81-95-819-7260
ClinicalTrials.gov Identifier: NCT05090410

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer
Principal Investigators: Xiuning Le, MD, PhD. MD Anderson Cancer Center. Houston, Texas, United States, 77030.
Contact: Xiuning Le, MD, PhD. Phone: +1 713-792-6980
ClinicalTrials.gov Identifier: NCT05704634

Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Principal Investigators: Luis Sainz, MD. Hospital de la Santa Creu i Sant Pau. Barcelona, Spain, 08041
Contact: Luis Sainz, MD. Phone: +34 679743541 ext +34
ClinicalTrials.gov Identifier: NCT05045001

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
Principal Investigators: Maria Vehreschild, Prof. Klinikum Der Johann Wolfgang Von Goethe Universitaet. Frankfurt am main, Germany, 60590
Contact: Frank vd Veerdonk, Dr. Phone: 0031243618819
ClinicalTrials.gov Identifier: NCT04979052

Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections
Principal Investigators: Louis CHAUVELOT, MD. Hopital Lyon Sud. Pierre-Bénite, Rhone, France, 69110
Contact: Florent Wallet, MD Phone: 0478861921 ext +33
ClinicalTrials.gov Identifier: NCT05536219

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Principal Investigators: Jennifer Eva Selfridge, MD, PhD. University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center. Cleveland, Ohio, United States, 44106
Contact: Jennifer E. Selfridge, MD, PhD. Phone: 18006412422
ClinicalTrials.gov Identifier: NCT05400122

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
Principal Investigators: Jose H. Lincona, MD. Brigham and Women’s Hospital Vaccine CRS [30007]. Boston, Massachusetts, United States, 02115
Contact: Jose H. Lincona, MD. Phone: 617-525-9433
ClinicalTrials.gov Identifier: NCT05781542

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)
Principal Investigators: Jo Lambert, MD, PhD. Ghent University Hospital. Gent, Belgium, 9000
Contact: Juul van den Reek, MD, PhD. Phone: 0031243613724
ClinicalTrials.gov Identifier: NCT04340076

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)
Principal Investigators: Andrej SPEC, MD. Washington University. Saint Louis, Missouri, United States, 63110
Contact: Michel MORRE, DVM. Phone: +33603357060
ClinicalTrials.gov Identifier: NCT04154826

Exit mobile version